GlassScriptPhysician profile
Michael J Barondes
NPI 1760496830
$2,894.76
in general payments reported to CMS, 2019-2025
27 companies · $635 in 2025
The $635 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $391 · 2021: $528 · 2022: $360 · 2023: $212 · 2024: $425 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $418.38 | 2019-2025 | |
| Alimera Sciences, INC. | $217.26 | 2019-2024 | Iluvien, Yutiq |
| Allergan, INC. | $214.95 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $194.66 | 2019-2021 | |
| Biotissue Holdings INC. | $189.87 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $185.73 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $183.79 | 2022-2025 | Eylea, Eylea Hd |
| Kala Pharmaceuticals, INC. | $153.02 | 2019-2021 | |
| Alcon Vision LLC | $138.69 | 2023-2025 | Rocklatan, Hydrus Microstent, Clareon |
| Aerie Pharmaceuticals, INC. | $125.22 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $118.62 | 2019-2022 | |
| Dompe US, INC. | $108.20 | 2020-2025 | Oxervate |
| Lensar, INC. | $95.48 | 2025 | Lensar Laser System |
| Bausch & Lomb Americas INC. | $80.75 | 2022-2024 | Vyzulta, Miebo, Xiidra |
| Mallinckrodt Hospital Products INC. | $63.65 | 2025 | Acthar |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $57.83 | 2025 | Vevye, Iheezo |
| Optos, INC. | $48.49 | 2021 | |
| Genentech USA, INC. | $45.99 | 2022 | |
| Ani Pharmaceuticals, INC. | $45.31 | 2025 | Iluvien, Yutiq |
| Amgen INC. | $42.39 | 2024-2025 | Tepezza |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Ocular Therapeutix, INC. | $31.10 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $27.98 | 2025 | Tecnis Simplicity |
| Rxsight INC | $20.98 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Biogen, INC. | $20.71 | 2022 | |
| Akorn Operating Company LLC | $15.60 | 2021 | |
| Horizon Therapeutics Plc | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Barondes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.